Design Therapeutics, Inc.

NasdaqGS:DSGN Stock Report

Market Cap: US$198.7m

Design Therapeutics Management

Management criteria checks 3/4

Design Therapeutics' CEO is Pratik Shah, appointed in Aug 2023, has a tenure of 1.75 years. total yearly compensation is $789.80K, comprised of 50% salary and 50% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $454.72K. The average tenure of the management team and the board of directors is 0.2 years and 4.5 years respectively.

Key information

Pratik Shah

Chief executive officer

US$789.8k

Total compensation

CEO salary percentage50.0%
CEO tenure1.8yrs
CEO ownership0.2%
Management average tenureless than a year
Board average tenure4.5yrs

Recent management updates

Recent updates

Design Therapeutics: Not A Complete Washout Despite Setback

Jan 31

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Oct 04
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Jun 19
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Mar 15
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Nov 16
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Jun 06
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Feb 09
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Oct 25
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics GAAP EPS of -$0.27 misses by $0.02

Aug 08

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Jul 02
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Mar 18
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Dec 03
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Aug 18
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

CEO Compensation Analysis

How has Pratik Shah's remuneration changed compared to Design Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$56m

Dec 31 2024US$790kUS$395k

-US$50m

Sep 30 2024n/an/a

-US$48m

Jun 30 2024n/an/a

-US$51m

Mar 31 2024n/an/a

-US$59m

Dec 31 2023US$6mUS$361k

-US$67m

Sep 30 2023n/an/a

-US$72m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$69m

Dec 31 2022US$5mUS$338k

-US$63m

Sep 30 2022n/an/a

-US$57m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$585kUS$310k

-US$36m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$400kUS$250k

-US$8m

Compensation vs Market: Pratik's total compensation ($USD789.80K) is below average for companies of similar size in the US market ($USD1.62M).

Compensation vs Earnings: Pratik's compensation has been consistent with company performance over the past year.

CEO

Pratik Shah (54 yo)

1.8yrs

Tenure

US$789,800

Compensation

Dr. Pratik Shah, Ph D., is an Executive Chairperson at Design Therapeutics, Inc. since December 2017 and serves as its President, Chief Executive Officer and Principal Financial Officer since August 25, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Pratik Shah
Co-Founder1.8yrsUS$789.80k0.23%
$ 454.7k
Sean Jeffries
Chief Operating Officer4.3yrsUS$1.32m1.43%
$ 2.8m
Aseem Ansari
Co-Founder & Scientific Advisorno datano data13.51%
$ 26.8m
Julie Burgess
Chief Accounting Officer3.7yrsno datano data
Doane Chilcoat
Chief Technology Officerless than a yearno datano data
Mustapha Parekh
General Counselno datano datano data
Tadimeti Rao
Chief Scientific Officerless than a yearno datano data
Jim Kerr
Chief of Manufacturing & Product Developmentless than a yearno datano data
Chengzhi Zhang
Chief Chemistless than a yearno datano data
Chris Storgard
Chief Medical Officerless than a yearno datano data

0.2yrs

Average Tenure

54yo

Average Age

Experienced Management: DSGN's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Pratik Shah
Co-Founder7.4yrsUS$789.80k0.23%
$ 454.7k
Aseem Ansari
Co-Founder & Scientific Advisorno datano data13.51%
$ 26.8m
John Schmid
Independent Director4.5yrsUS$117.98k0.10%
$ 201.7k
Rodney Lappe
Independent Director5.8yrsUS$116.98k0.23%
$ 465.6k
Simeon George
Lead Independent Director5.3yrsUS$137.98k0%
$ 0
Deepa Prasad
Independent Director3.9yrsUS$99.48k0.035%
$ 70.0k
Heather Berger
Independent Director3.9yrsUS$105.11k0.0023%
$ 4.6k
Arsani William
Independent Director4.3yrsUS$111.48k0%
$ 0

4.5yrs

Average Tenure

48yo

Average Age

Experienced Board: DSGN's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 12:22
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Design Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarGoldman Sachs
Joseph SchwartzLeerink Partners LLC
Yasmeen RahimiPiper Sandler Companies